Jesse I Treu - Net Worth and Insider Trading

Jesse I Treu Net Worth

The estimated net worth of Jesse I Treu is at least $137 Million dollars as of 2024-11-06. Jesse I Treu is the 10% Owner of Achillion Pharmaceuticals Inc and owns about 8,032,129 shares of Achillion Pharmaceuticals Inc (ACHN) stock worth over $54 Million. Jesse I Treu is the Director of Veracyte Inc and owns about 1,234,930 shares of Veracyte Inc (VCYT) stock worth over $44 Million. Jesse I Treu is also the 10% Owner of Zogenix Inc and owns about 825,323 shares of Zogenix Inc (ZGNX) stock worth over $22 Million. Besides these, Jesse I Treu also holds Aldeyra Therapeutics Inc (ALDX) , Esperion Therapeutics Inc (ESPR) , Alimera Sciences Inc (ALIM) , Ocera Therapeutics Inc (OCRX) , Clovis Oncology Inc (CLVSQ) , Orexigen Therapeutics Inc (OREXQ) , Novation Companies Inc (NOVCQ) , Regado Biosciences Inc (RGDO) . Details can be seen in Jesse I Treu's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Jesse I Treu has not made any transactions after 2019-03-26 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Jesse I Treu

Jesse I Treu Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jesse I Treu owns 31 companies in total, including Aldeyra Therapeutics Inc (ALDX) , Obalon Therapeutics Inc (OBLN) , and Adynxx Inc (ADYX) among others .

Click here to see the complete history of Jesse I Treu’s form 4 insider trades.

Insider Ownership Summary of Jesse I Treu

Ticker	Comapny	Transaction Date	Type of Owner
ALDX	Aldeyra Therapeutics Inc	2019-03-26	director & 10 percent owner
OBLN	Obalon Therapeutics Inc	2019-08-06	10 percent owner
ADYX	Adynxx Inc	2019-05-03	10 percent owner
		2019-03-04	director & 10 percent owner
		2018-08-21	10 percent owner
		2017-12-18	10 percent owner
		2017-12-11	10 percent owner
		2013-11-13	director & 10 percent owner
		2016-11-01	10 percent owner
		2016-09-09	10 percent owner
		2013-09-24	10 percent owner
		2016-03-02	10 percent owner
		2015-06-24	10 percent owner
		2015-05-06	10 percent owner
		2013-07-01	10 percent owner
		2014-11-19	10 percent owner
		2014-10-15	10 percent owner
		2014-08-12	10 percent owner
		2014-07-31	10 percent owner
		2014-03-17	10 percent owner
		2011-06-02	10 percent owner
		2011-11-21	10 percent owner
		2013-01-18	10 percent owner
		2013-01-14	10 percent owner
		2011-12-22	10 percent owner
		2011-09-16	10 percent owner
		2006-05-09	10 percent owner
		2006-04-12	10 percent owner
		2004-06-25	10 percent owner
		2004-05-12	10 percent owner
		2016-10-05	10 percent owner

Jesse I Treu Latest Holdings Summary

Jesse I Treu currently owns a total of 11 stocks. Among these stocks, Jesse I Treu owns 8,032,129 shares of Achillion Pharmaceuticals Inc (ACHN) as of August 20, 2010, with a value of $54 Million and a weighting of 39.6%. Jesse I Treu owns 1,234,930 shares of Veracyte Inc (VCYT) as of March 4, 2019, with a value of $44 Million and a weighting of 32.36%. Jesse I Treu also owns 825,323 shares of Zogenix Inc (ZGNX) as of November 29, 2010, with a value of $22 Million and a weighting of 16.06%. The other 8 stocks Aldeyra Therapeutics Inc (ALDX) , Esperion Therapeutics Inc (ESPR) , Alimera Sciences Inc (ALIM) , Ocera Therapeutics Inc (OCRX) , Clovis Oncology Inc (CLVSQ) , Orexigen Therapeutics Inc (OREXQ) , Novation Companies Inc (NOVCQ) , Regado Biosciences Inc (RGDO) have a combined weighting of 11.98% among all his current holdings.

Latest Holdings of Jesse I Treu

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
ACHN	Achillion Pharmaceuticals Inc	2010-08-20	8,032,129	6.76	54,297,192
VCYT	Veracyte Inc	2019-03-04	1,234,930	35.93	44,371,035
ZGNX	Zogenix Inc	2010-11-29	825,323	26.68	22,019,618
ALDX	Aldeyra Therapeutics Inc	2019-03-26	1,885,854	5.27	9,938,451
ESPR	Esperion Therapeutics Inc	2013-07-01	2,102,188	2.12	4,456,639
ALIM	Alimera Sciences Inc	2011-06-02	279,297	5.54	1,547,305
OCRX	Ocera Therapeutics Inc	2013-07-15	246,386	1.79	441,031
CLVSQ	Clovis Oncology Inc	2011-11-21	3,041,950	0.02	45,629
OREXQ	Orexigen Therapeutics Inc	2011-12-22	301,806	0.01	1,600
NOVCQ	Novation Companies Inc	2006-05-15	1,062,474	0.00	106
RGDO	Regado Biosciences Inc	2013-08-27	2,603,208	0.00	0

Holding Weightings of Jesse I Treu

Jesse I Treu Form 4 Trading Tracker

According to the SEC Form 4 filings, Jesse I Treu has made a total of 0 transactions in Achillion Pharmaceuticals Inc (ACHN) over the past 5 years. The most-recent trade in Achillion Pharmaceuticals Inc is the sale of 0 shares on August 20, 2010, which brought Jesse I Treu around $0.

According to the SEC Form 4 filings, Jesse I Treu has made a total of 0 transactions in Veracyte Inc (VCYT) over the past 5 years. The most-recent trade in Veracyte Inc is the sale of 1,052,151 shares on March 4, 2019, which brought Jesse I Treu around $21 Million.

According to the SEC Form 4 filings, Jesse I Treu has made a total of 0 transactions in Zogenix Inc (ZGNX) over the past 5 years. The most-recent trade in Zogenix Inc is the acquisition of 293,750 shares on November 29, 2010, which cost Jesse I Treu around $9 Million.

More details on Jesse I Treu's insider transactions can be found in the Insider Trading History of Jesse I Treu table.

Insider Trading History of Jesse I Treu

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jesse I Treu Trading Performance

GuruFocus tracks the stock performance after each of Jesse I Treu's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jesse I Treu is 13.44%. GuruFocus also compares Jesse I Treu's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jesse I Treu within 3 months outperforms 5 times out of 21 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Jesse I Treu's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Jesse I Treu

Average Return

Average return per transaction

Outperforming Transactions

6 out of 21 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	13.79
Relative Return to S&P 500(%)	10.5

Jesse I Treu Ownership Network

Ownership Network List of Jesse I Treu

No Data

Ownership Network Relation of Jesse I Treu

Jesse I Treu Owned Company Details

What does Aldeyra Therapeutics Inc do?

Who are the key executives at Aldeyra Therapeutics Inc?

Jesse I Treu is the director & 10 percent owner of Aldeyra Therapeutics Inc. Other key executives at Aldeyra Therapeutics Inc include Chief Development Officer Stephen Machatha , See Remarks Bruce Greenberg , and 10 percent owner Perceptive Life Sciences Master Fund Ltd .

Aldeyra Therapeutics Inc (ALDX) Insider Trades Summary

Over the past 18 months, Jesse I Treu made no insider transaction in Aldeyra Therapeutics Inc (ALDX). Other recent insider transactions involving Aldeyra Therapeutics Inc (ALDX) include a net sale of 2,074,234 shares made by Perceptive Life Sciences Master Fund Ltd , a net sale of 57,346 shares made by Stephen Machatha , and a net sale of 37,236 shares made by Bruce Greenberg .

In summary, during the past 3 months, insiders sold 26,875 shares of Aldeyra Therapeutics Inc (ALDX) in total and bought 0 shares, with a net sale of 26,875 shares. During the past 18 months, 3,034,319 shares of Aldeyra Therapeutics Inc (ALDX) were sold and 682,265 shares were bought by its insiders, resulting in a net sale of 2,352,054 shares.

Aldeyra Therapeutics Inc (ALDX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aldeyra Therapeutics Inc Insider Transactions

No Available Data

What does Obalon Therapeutics Inc do?

Who are the key executives at Obalon Therapeutics Inc?

Jesse I Treu is the 10 percent owner of Obalon Therapeutics Inc. Other key executives at Obalon Therapeutics Inc include director & President & CEO & Exec Chairman Andrew P Rasdal , Chief Financial Officer Nooshin Hussainy , and Chief Technology Officer Mark Brister .

Obalon Therapeutics Inc (OBLN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Obalon Therapeutics Inc (OBLN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Obalon Therapeutics Inc (OBLN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Obalon Therapeutics Inc (OBLN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Obalon Therapeutics Inc Insider Transactions

No Available Data

What does Adynxx Inc do?

Who are the key executives at Adynxx Inc?

Jesse I Treu is the 10 percent owner of Adynxx Inc. Other key executives at Adynxx Inc include 10 percent owner David Bonderman , CHIEF MEDICAL OFFICER Donald C. Manning , and 10 percent owner Domain Partners Viii, L.p. .

Adynxx Inc (ADYX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Adynxx Inc (ADYX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Adynxx Inc (ADYX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Adynxx Inc (ADYX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Adynxx Inc Insider Transactions

No Available Data

What does Veracyte Inc do?

Who are the key executives at Veracyte Inc?

Jesse I Treu is the director & 10 percent owner of Veracyte Inc. Other key executives at Veracyte Inc include Chief Commercial Officer-CLIA John Leite , Chief Scientific & Med Officer Phillip G. Febbo , and director & President & CEO Bonnie H Anderson .

Veracyte Inc (VCYT) Insider Trades Summary

Over the past 18 months, Jesse I Treu made no insider transaction in Veracyte Inc (VCYT). Other recent insider transactions involving Veracyte Inc (VCYT) include a net sale of 131,749 shares made by Evan/ Fa Jones , a net sale of 12,841 shares made by Muna Bhanji , and a net sale of 13,870 shares made by Karin Eastham .

In summary, during the past 3 months, insiders sold 75,491 shares of Veracyte Inc (VCYT) in total and bought 0 shares, with a net sale of 75,491 shares. During the past 18 months, 195,216 shares of Veracyte Inc (VCYT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 195,216 shares.

Veracyte Inc (VCYT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Veracyte Inc Insider Transactions

No Available Data

What does Bionano Genomics Inc do?

Who are the key executives at Bionano Genomics Inc?

Jesse I Treu is the 10 percent owner of Bionano Genomics Inc. Other key executives at Bionano Genomics Inc include Chief Financial Officer Gulsen Kama , director & President and CEO R. Erik Holmlin , and Chief Financial Officer Christopher P. Stewart .

Bionano Genomics Inc (BNGO) Insider Trades Summary

Over the past 18 months, Jesse I Treu made no insider transaction in Bionano Genomics Inc (BNGO). Other recent insider transactions involving Bionano Genomics Inc (BNGO) include a net purchase of 65,789 shares made by Hannah Mamuszka , a net purchase of 50,000 shares made by Christopher P. Stewart , and a net purchase of 15,000 shares made by R. Erik Holmlin .

In summary, during the past 3 months, insiders sold 0 shares of Bionano Genomics Inc (BNGO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Bionano Genomics Inc (BNGO) were sold and 13,079 shares were bought by its insiders, resulting in a net purchase of 13,079 shares.

Bionano Genomics Inc (BNGO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Bionano Genomics Inc Insider Transactions

No Available Data

What does Dicerna Pharmaceuticals Inc do?

Who are the key executives at Dicerna Pharmaceuticals Inc?

Jesse I Treu is the 10 percent owner of Dicerna Pharmaceuticals Inc. Other key executives at Dicerna Pharmaceuticals Inc include See Remarks Bob D Brown , EVP & Chief Medical Officer Shreeram Aradhye , and director & President and CEO Douglas Fambrough .

Dicerna Pharmaceuticals Inc (DRNA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Dicerna Pharmaceuticals Inc (DRNA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Dicerna Pharmaceuticals Inc (DRNA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Dicerna Pharmaceuticals Inc (DRNA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Dicerna Pharmaceuticals Inc Insider Transactions

No Available Data

What does Ocera Therapeutics Inc do?

Who are the key executives at Ocera Therapeutics Inc?

Jesse I Treu is the 10 percent owner of Ocera Therapeutics Inc. Other key executives at Ocera Therapeutics Inc include 10 percent owner Brian H Dovey , 10 percent owner Domain Partners Viii, L.p. , and 10 percent owner Dp Viii Associates, L.p. .

Ocera Therapeutics Inc (OCRX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Ocera Therapeutics Inc (OCRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Ocera Therapeutics Inc (OCRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Ocera Therapeutics Inc (OCRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ocera Therapeutics Inc Insider Transactions

No Available Data

What does Tandem Diabetes Care Inc do?

Who are the key executives at Tandem Diabetes Care Inc?

Jesse I Treu is the director & 10 percent owner of Tandem Diabetes Care Inc. Other key executives at Tandem Diabetes Care Inc include SVP & General Counsel Shannon Marie Hansen , Senior Vice President and CFO Leigh Vosseller , and GENERAL COUNSEL David B Berger .

Tandem Diabetes Care Inc (TNDM) Insider Trades Summary

Over the past 18 months, Jesse I Treu made no insider transaction in Tandem Diabetes Care Inc (TNDM). Other recent insider transactions involving Tandem Diabetes Care Inc (TNDM) include a net purchase of 10,000 shares made by Dick Allen , a net purchase of 6,200 shares made by Leigh Vosseller , and a net purchase of 3,000 shares made by Peyton R Howell .

In summary, during the past 3 months, insiders sold 0 shares of Tandem Diabetes Care Inc (TNDM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 5,000 shares of Tandem Diabetes Care Inc (TNDM) were sold and 27,135 shares were bought by its insiders, resulting in a net purchase of 22,135 shares.

Tandem Diabetes Care Inc (TNDM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Tandem Diabetes Care Inc Insider Transactions

No Available Data

What does Regado Biosciences Inc do?

Who are the key executives at Regado Biosciences Inc?

Jesse I Treu is the 10 percent owner of Regado Biosciences Inc. Other key executives at Regado Biosciences Inc include 10 percent owner Associates Domain , Chief Medical Officer Eric Lefebvre , and Chief Financial Officer Christopher Peetz .

Regado Biosciences Inc (RGDO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Regado Biosciences Inc (RGDO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Regado Biosciences Inc (RGDO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Regado Biosciences Inc (RGDO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Regado Biosciences Inc Insider Transactions

No Available Data

What does CoLucid Pharmaceuticals Inc do?

Who are the key executives at CoLucid Pharmaceuticals Inc?

Jesse I Treu is the 10 percent owner of CoLucid Pharmaceuticals Inc. Other key executives at CoLucid Pharmaceuticals Inc include 10 percent owner Pappas Capital, Llc , 10 percent owner Lilly Eli & Co , and 10 percent owner Tvm Life Science Ventures Vii L.p. .

CoLucid Pharmaceuticals Inc (CLCD) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of CoLucid Pharmaceuticals Inc (CLCD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of CoLucid Pharmaceuticals Inc (CLCD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

CoLucid Pharmaceuticals Inc (CLCD)'s detailed insider trading history can be found in Insider Trading Tracker table.

CoLucid Pharmaceuticals Inc Insider Transactions

No Available Data

What does Evoke Pharma Inc do?

Who are the key executives at Evoke Pharma Inc?

Jesse I Treu is the 10 percent owner of Evoke Pharma Inc. Other key executives at Evoke Pharma Inc include director & President and CEO David A Gonyer , Exec VP & Chief Bus. Officer Matthew J D'onofrio , and 10 percent owner Lvp Gp Iii, Llc .

Evoke Pharma Inc (EVOK) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Evoke Pharma Inc (EVOK) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Evoke Pharma Inc (EVOK) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Evoke Pharma Inc (EVOK)'s detailed insider trading history can be found in Insider Trading Tracker table.

Evoke Pharma Inc Insider Transactions

No Available Data

What does Syndax Pharmaceuticals Inc do?

Who are the key executives at Syndax Pharmaceuticals Inc?

Jesse I Treu is the 10 percent owner of Syndax Pharmaceuticals Inc. Other key executives at Syndax Pharmaceuticals Inc include Chief Financial Officer Keith A. Goldan , director & Chief Executive Officer Briggs Morrison , and President & Head of R&D Neil Gallagher .

Syndax Pharmaceuticals Inc (SNDX) Insider Trades Summary

Over the past 18 months, Jesse I Treu made no insider transaction in Syndax Pharmaceuticals Inc (SNDX). Other recent insider transactions involving Syndax Pharmaceuticals Inc (SNDX) include a net sale of 211,420 shares made by Briggs Morrison , a net purchase of 673 shares made by Keith A. Goldan , and a net sale of 83,000 shares made by William Meury .

In summary, during the past 3 months, insiders sold 0 shares of Syndax Pharmaceuticals Inc (SNDX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 294,997 shares of Syndax Pharmaceuticals Inc (SNDX) were sold and 1,250 shares were bought by its insiders, resulting in a net sale of 293,747 shares.

Syndax Pharmaceuticals Inc (SNDX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Syndax Pharmaceuticals Inc Insider Transactions

No Available Data

What does Glaukos Corp do?

Who are the key executives at Glaukos Corp?

Jesse I Treu is the 10 percent owner of Glaukos Corp. Other key executives at Glaukos Corp include CFO & SVP Corporate Development Joseph E Gilliam , SVP & Chief Financial Officer Alex R. Thurman , and director & 10 percent owner & Chief Executive Officer Thomas William Burns .

Glaukos Corp (GKOS) Insider Trades Summary

Over the past 18 months, Jesse I Treu made no insider transaction in Glaukos Corp (GKOS). Other recent insider transactions involving Glaukos Corp (GKOS) include a net sale of 311,429 shares made by Joseph E Gilliam , a net sale of 520,000 shares made by Thomas William Burns , and a net sale of 6,762 shares made by Alex R. Thurman .

In summary, during the past 3 months, insiders sold 41,525 shares of Glaukos Corp (GKOS) in total and bought 0 shares, with a net sale of 41,525 shares. During the past 18 months, 942,098 shares of Glaukos Corp (GKOS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 942,098 shares.

Glaukos Corp (GKOS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Glaukos Corp Insider Transactions

No Available Data

What does aTyr Pharma Inc do?

Who are the key executives at aTyr Pharma Inc?

Jesse I Treu is the 10 percent owner of aTyr Pharma Inc. Other key executives at aTyr Pharma Inc include Chief Financial Officer Jill Marie Broadfoot , Chief Medical Officer Sanjay Shukla , and See Remarks Nancy Krueger .

aTyr Pharma Inc (ATYR) Insider Trades Summary

Over the past 18 months, Jesse I Treu made no insider transaction in aTyr Pharma Inc (ATYR). Other recent insider transactions involving aTyr Pharma Inc (ATYR) include a net purchase of 65,000 shares made by Sanjay Shukla , a net purchase of 300,000 shares made by Paul Schimmel , and a net purchase of 3,410 shares made by Jill Marie Broadfoot .

In summary, during the past 3 months, insiders sold 0 shares of aTyr Pharma Inc (ATYR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,590 shares of aTyr Pharma Inc (ATYR) were sold and 425,000 shares were bought by its insiders, resulting in a net purchase of 423,410 shares.

aTyr Pharma Inc (ATYR)'s detailed insider trading history can be found in Insider Trading Tracker table.

aTyr Pharma Inc Insider Transactions

No Available Data

What does Esperion Therapeutics Inc do?

Who are the key executives at Esperion Therapeutics Inc?

Jesse I Treu is the 10 percent owner of Esperion Therapeutics Inc. Other key executives at Esperion Therapeutics Inc include Chief Commercial Officer Eric Warren , Chief Operating Officer Sheldon L. Koenig , and Chief Medical Officer Joanne M. Foody .

Esperion Therapeutics Inc (ESPR) Insider Trades Summary

Over the past 18 months, Jesse I Treu made no insider transaction in Esperion Therapeutics Inc (ESPR). Other recent insider transactions involving Esperion Therapeutics Inc (ESPR) include a net sale of 7,679 shares made by Eric Warren , a net purchase of 5,450 shares made by Sheldon L. Koenig , and a net sale of 4,202 shares made by Joanne M. Foody .

In summary, during the past 3 months, insiders sold 17,476 shares of Esperion Therapeutics Inc (ESPR) in total and bought 0 shares, with a net sale of 17,476 shares. During the past 18 months, 26,431 shares of Esperion Therapeutics Inc (ESPR) were sold and 59,611 shares were bought by its insiders, resulting in a net purchase of 33,180 shares.

Esperion Therapeutics Inc (ESPR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Esperion Therapeutics Inc Insider Transactions

No Available Data

What does Evofem Biosciences Inc do?

Who are the key executives at Evofem Biosciences Inc?

Jesse I Treu is the 10 percent owner of Evofem Biosciences Inc. Other key executives at Evofem Biosciences Inc include Chief Financial Officer Yan Zhang , director & 10 percent owner Kim P. Kamdar , and Chief Commercial Officer Atkinson Katherine Cocca .

Evofem Biosciences Inc (EVFM) Insider Trades Summary

Over the past 18 months, Jesse I Treu made no insider transaction in Evofem Biosciences Inc (EVFM). Other recent insider transactions involving Evofem Biosciences Inc (EVFM) include a net sale of 104 shares made by Yan Zhang , and a net sale of 10 shares made by Kim P. Kamdar .

In summary, during the past 3 months, insiders sold 0 shares of Evofem Biosciences Inc (EVFM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 114 shares of Evofem Biosciences Inc (EVFM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 114 shares.

Evofem Biosciences Inc (EVFM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Evofem Biosciences Inc Insider Transactions

No Available Data

What does Atara Biotherapeutics Inc do?

Who are the key executives at Atara Biotherapeutics Inc?

Jesse I Treu is the 10 percent owner of Atara Biotherapeutics Inc. Other key executives at Atara Biotherapeutics Inc include EVP & Global Head RA & Quality Jill Henrich , EVP & Chief Sci. & Tech Officer Anhco Nguyen , and SVP & CFO Eric J Hyllengren .

Atara Biotherapeutics Inc (ATRA) Insider Trades Summary

Over the past 18 months, Jesse I Treu made no insider transaction in Atara Biotherapeutics Inc (ATRA). Other recent insider transactions involving Atara Biotherapeutics Inc (ATRA) include a net sale of 204,620 shares made by Pascal Touchon , a net sale of 68,971 shares made by Amar Murugan , and a net sale of 64,459 shares made by Eric J Hyllengren .

In summary, during the past 3 months, insiders sold 8,050 shares of Atara Biotherapeutics Inc (ATRA) in total and bought 0 shares, with a net sale of 8,050 shares. During the past 18 months, 27,448 shares of Atara Biotherapeutics Inc (ATRA) were sold and 32,673 shares were bought by its insiders, resulting in a net purchase of 5,225 shares.

Atara Biotherapeutics Inc (ATRA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Atara Biotherapeutics Inc Insider Transactions

No Available Data

What does Otonomy Inc do?

Who are the key executives at Otonomy Inc?

Jesse I Treu is the 10 percent owner of Otonomy Inc. Other key executives at Otonomy Inc include Chief Technical Officer Savel Robert Michael Ii , Chief Scientific Officer Alan Charles Foster , and director & President & CEO David Allen Weber .

Otonomy Inc (OTIC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Otonomy Inc (OTIC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Otonomy Inc (OTIC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Otonomy Inc (OTIC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Otonomy Inc Insider Transactions

No Available Data

What does Marinus Pharmaceuticals Inc do?

Who are the key executives at Marinus Pharmaceuticals Inc?

Jesse I Treu is the 10 percent owner of Marinus Pharmaceuticals Inc. Other key executives at Marinus Pharmaceuticals Inc include Chief Commercial Officer Christina Shafer , CFO Steven Pfanstiel , and Chief Medical Officer Joseph Hulihan .

Marinus Pharmaceuticals Inc (MRNS) Insider Trades Summary

Over the past 18 months, Jesse I Treu made no insider transaction in Marinus Pharmaceuticals Inc (MRNS). Other recent insider transactions involving Marinus Pharmaceuticals Inc (MRNS) include a net sale of 18,588 shares made by Scott Braunstein , a net sale of 7,730 shares made by Joseph Hulihan , and a net sale of 7,461 shares made by Steven Pfanstiel .

In summary, during the past 3 months, insiders sold 0 shares of Marinus Pharmaceuticals Inc (MRNS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 45,796 shares of Marinus Pharmaceuticals Inc (MRNS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 45,796 shares.

Marinus Pharmaceuticals Inc (MRNS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Marinus Pharmaceuticals Inc Insider Transactions

No Available Data

What does Achaogen Inc do?

Who are the key executives at Achaogen Inc?

Jesse I Treu is the 10 percent owner of Achaogen Inc. Other key executives at Achaogen Inc include 10 percent owner Robert W Duggan , Chief Operating Officer Elizabeth Bhatt , and See Remarks Gary Loeb .

Achaogen Inc (AKAOQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Achaogen Inc (AKAOQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Achaogen Inc (AKAOQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Achaogen Inc (AKAOQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Achaogen Inc Insider Transactions

No Available Data

What does Alimera Sciences Inc do?

Who are the key executives at Alimera Sciences Inc?

Jesse I Treu is the 10 percent owner of Alimera Sciences Inc. Other key executives at Alimera Sciences Inc include 10 percent owner Caligan Partners Lp , other: Chairman Emeritus C. Daniel Myers , and 10 percent owner David Edward Johnson .

Alimera Sciences Inc (ALIM) Insider Trades Summary

Over the past 18 months, Jesse I Treu made no insider transaction in Alimera Sciences Inc (ALIM). Other recent insider transactions involving Alimera Sciences Inc (ALIM) include a net sale of 0 shares made by Caligan Partners Lp , and a net purchase of 1,401,901 shares made by Adam Morgan .

In summary, during the past 3 months, insiders sold 0 shares of Alimera Sciences Inc (ALIM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 579,000 shares of Alimera Sciences Inc (ALIM) were sold and 1,980,901 shares were bought by its insiders, resulting in a net purchase of 1,401,901 shares.

Alimera Sciences Inc (ALIM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Alimera Sciences Inc Insider Transactions

No Available Data

What does Clovis Oncology Inc do?

Who are the key executives at Clovis Oncology Inc?

Jesse I Treu is the 10 percent owner of Clovis Oncology Inc. Other key executives at Clovis Oncology Inc include See Remarks Thomas C. Harding , See Remarks Gillian C Ivers-read , and See remarks Lindsey Rolfe .

Clovis Oncology Inc (CLVSQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Clovis Oncology Inc (CLVSQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Clovis Oncology Inc (CLVSQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Clovis Oncology Inc (CLVSQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Clovis Oncology Inc Insider Transactions

No Available Data

What does Achillion Pharmaceuticals Inc do?

Who are the key executives at Achillion Pharmaceuticals Inc?

Jesse I Treu is the 10 percent owner of Achillion Pharmaceuticals Inc. Other key executives at Achillion Pharmaceuticals Inc include EVP & Chief Commercial Officer Paul E Firuta , EVP & Chief Medical Officer Steven Zelenkofske , and General Counsel Martha E Manning .

Achillion Pharmaceuticals Inc (ACHN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Achillion Pharmaceuticals Inc (ACHN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Achillion Pharmaceuticals Inc (ACHN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Achillion Pharmaceuticals Inc (ACHN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Achillion Pharmaceuticals Inc Insider Transactions

No Available Data

What does Celator Pharmaceuticals Inc do?

Who are the key executives at Celator Pharmaceuticals Inc?

Jesse I Treu is the 10 percent owner of Celator Pharmaceuticals Inc. Other key executives at Celator Pharmaceuticals Inc include other: Member of a 10% Group Eric W Roberts , other: See Remarks Section Cdk Associates, L.l.c. , and VP and Chief Financial Officer Fred M Powell .

Celator Pharmaceuticals Inc (CPXX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Celator Pharmaceuticals Inc (CPXX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Celator Pharmaceuticals Inc (CPXX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Celator Pharmaceuticals Inc (CPXX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Celator Pharmaceuticals Inc Insider Transactions

No Available Data

What does Orexigen Therapeutics Inc do?

Who are the key executives at Orexigen Therapeutics Inc?

Jesse I Treu is the 10 percent owner of Orexigen Therapeutics Inc. Other key executives at Orexigen Therapeutics Inc include 10 percent owner Baupost Group Gp, L.l.c. , 10 percent owner Baupost Group Llc/ma , and 10 percent owner Seth A Klarman .

Orexigen Therapeutics Inc (OREXQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Orexigen Therapeutics Inc (OREXQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Orexigen Therapeutics Inc (OREXQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Orexigen Therapeutics Inc (OREXQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Orexigen Therapeutics Inc Insider Transactions

No Available Data

What does Zogenix Inc do?

Who are the key executives at Zogenix Inc?

Jesse I Treu is the 10 percent owner of Zogenix Inc. Other key executives at Zogenix Inc include EVP & CHIEF COMMERCIAL OFFICER Ashish M Sagrolikar , EVP/Chief Development Officer Gail M Farfel , and director & President and CEO Stephen J Farr .

Zogenix Inc (ZGNX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Zogenix Inc (ZGNX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Zogenix Inc (ZGNX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Zogenix Inc (ZGNX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Zogenix Inc Insider Transactions

No Available Data

What does Paratek Pharmaceuticals Inc do?

Who are the key executives at Paratek Pharmaceuticals Inc?

Jesse I Treu is the 10 percent owner of Paratek Pharmaceuticals Inc. Other key executives at Paratek Pharmaceuticals Inc include CLO & General Counsel & Sec. William M. Haskel , President & Chief Commercial Adam Woodrow , and Chief Development & Regulatory Randall B. Brenner .

Paratek Pharmaceuticals Inc (PRTK) Insider Trades Summary

Over the past 18 months, Jesse I Treu made no insider transaction in Paratek Pharmaceuticals Inc (PRTK). Other recent insider transactions involving Paratek Pharmaceuticals Inc (PRTK) include a net sale of 48,967 shares made by Evan Loh , a net sale of 34,526 shares made by William M. Haskel , and a net sale of 31,250 shares made by Michael Bigham .

In summary, during the past 3 months, insiders sold 0 shares of Paratek Pharmaceuticals Inc (PRTK) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 142,346 shares of Paratek Pharmaceuticals Inc (PRTK) were sold and 0 shares were bought by its insiders, resulting in a net sale of 142,346 shares.

Paratek Pharmaceuticals Inc (PRTK)'s detailed insider trading history can be found in Insider Trading Tracker table.

Paratek Pharmaceuticals Inc Insider Transactions

No Available Data

What does Vanda Pharmaceuticals Inc do?

Who are the key executives at Vanda Pharmaceuticals Inc?

Jesse I Treu is the 10 percent owner of Vanda Pharmaceuticals Inc. Other key executives at Vanda Pharmaceuticals Inc include VP & Acting CFO & Treasurer Kevin Patrick Moran , director & Chief Executive Officer Mihael Hristos Polymeropoulos , and SVP & Business Development Gunther Birznieks .

Vanda Pharmaceuticals Inc (VNDA) Insider Trades Summary

Over the past 18 months, Jesse I Treu made no insider transaction in Vanda Pharmaceuticals Inc (VNDA). Other recent insider transactions involving Vanda Pharmaceuticals Inc (VNDA) include a net sale of 35,163 shares made by Kevin Patrick Moran , a net sale of 31,688 shares made by Timothy Williams , and a net sale of 20,451 shares made by Joakim Wijkstrom .

In summary, during the past 3 months, insiders sold 0 shares of Vanda Pharmaceuticals Inc (VNDA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 166,385 shares of Vanda Pharmaceuticals Inc (VNDA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 166,385 shares.

Vanda Pharmaceuticals Inc (VNDA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Vanda Pharmaceuticals Inc Insider Transactions

No Available Data

What does Senomyx Inc do?

Who are the key executives at Senomyx Inc?

Jesse I Treu is the 10 percent owner of Senomyx Inc. Other key executives at Senomyx Inc include director & President & CEO John Poyhonen , 10 percent owner Richard R Mashaal , and 10 percent owner Senvest Management, Llc .

Senomyx Inc (SNMX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Senomyx Inc (SNMX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Senomyx Inc (SNMX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Senomyx Inc (SNMX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Senomyx Inc Insider Transactions

No Available Data

What does NuVasive Inc do?

Who are the key executives at NuVasive Inc?

Jesse I Treu is the 10 percent owner of NuVasive Inc. Other key executives at NuVasive Inc include SVP & People and Culture Michael Farrington , Chief Accounting Officer Marc W. Rosenbaum , and director & Chief Executive Officer James Christopher Barry .

NuVasive Inc (NUVA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of NuVasive Inc (NUVA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of NuVasive Inc (NUVA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

NuVasive Inc (NUVA)'s detailed insider trading history can be found in Insider Trading Tracker table.

NuVasive Inc Insider Transactions

No Available Data

What does Reshape Lifesciences Inc do?

Who are the key executives at Reshape Lifesciences Inc?

Jesse I Treu is the 10 percent owner of Reshape Lifesciences Inc. Other key executives at Reshape Lifesciences Inc include Chief Financial Officer Thomas Stankovich , director & President and CEO Paul F. Hickey , and 10 percent owner Steven Boyd .

Reshape Lifesciences Inc (RSLS) Insider Trades Summary

Over the past 18 months, Jesse I Treu made no insider transaction in Reshape Lifesciences Inc (RSLS). Other recent insider transactions involving Reshape Lifesciences Inc (RSLS) include a net purchase of 16,686 shares made by Thomas Stankovich ,

In summary, during the past 3 months, insiders sold 0 shares of Reshape Lifesciences Inc (RSLS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 18 shares of Reshape Lifesciences Inc (RSLS) were sold and 305 shares were bought by its insiders, resulting in a net purchase of 288 shares.

Reshape Lifesciences Inc (RSLS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Reshape Lifesciences Inc Insider Transactions

No Available Data

Jesse I Treu Mailing Address

Above is the net worth, insider trading, and ownership report for Jesse I Treu. Currently GuruFocus does not have mailing address information for Jesse I Treu.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.